Aurinia Pharmaceuticals Inc (AUPH) Shares Bought by Wells Fargo & Company MN

Wells Fargo & Company MN lifted its holdings in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 13,197.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 26,595 shares of the biotechnology company’s stock after acquiring an additional 26,395 shares during the period. Wells Fargo & Company MN’s holdings in Aurinia Pharmaceuticals were worth $166,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Royal Bank of Canada raised its position in shares of Aurinia Pharmaceuticals by 8.6% during the 2nd quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 1,341 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Aurinia Pharmaceuticals by 1.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 81,950 shares of the biotechnology company’s stock worth $502,000 after acquiring an additional 931 shares in the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of Aurinia Pharmaceuticals during the 2nd quarter worth about $928,000. Ironwood Investment Management LLC raised its position in shares of Aurinia Pharmaceuticals by 20.8% during the 3rd quarter. Ironwood Investment Management LLC now owns 192,177 shares of the biotechnology company’s stock worth $1,205,000 after acquiring an additional 33,085 shares in the last quarter. Finally, AWM Investment Company Inc. raised its position in shares of Aurinia Pharmaceuticals by 17.5% during the 2nd quarter. AWM Investment Company Inc. now owns 352,500 shares of the biotechnology company’s stock worth $2,161,000 after acquiring an additional 52,500 shares in the last quarter. 28.08% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts have recently weighed in on the company. Royal Bank of Canada assumed coverage on Aurinia Pharmaceuticals in a research report on Thursday. They set an “outperform” rating and a $9.00 target price on the stock. Zacks Investment Research lowered Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, February 5th. ValuEngine raised Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. BidaskClub lowered Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, January 31st. Finally, Canaccord Genuity set a $11.00 target price on Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, November 17th. Two analysts have rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Aurinia Pharmaceuticals has an average rating of “Buy” and a consensus target price of $10.59.

Aurinia Pharmaceuticals Inc (NASDAQ AUPH) opened at $5.10 on Friday. Aurinia Pharmaceuticals Inc has a 12-month low of $3.17 and a 12-month high of $10.54.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million. Aurinia Pharmaceuticals had a negative return on equity of 25.56% and a negative net margin of 18,089.02%. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. equities analysts predict that Aurinia Pharmaceuticals Inc will post -1.08 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Aurinia Pharmaceuticals Inc (AUPH) Shares Bought by Wells Fargo & Company MN” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.com-unik.info/2018/02/10/aurinia-pharmaceuticals-inc-auph-shares-bought-by-wells-fargo-company-mn.html.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Institutional Ownership by Quarter for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit